Trump Announces Completion of Initial Drug Pricing Agreements
President Trump has finalized a series of drug pricing agreements, with the last deal involving Regeneron, marking the conclusion of 17 agreements pursued by the White House.
On April 23, 2026, President Trump celebrated the completion of a significant initiative aimed at reducing drug prices. This effort culminated in a deal with Regeneron, which was the final agreement among a total of 17 sought by the administration.
The announcement highlights the administration's ongoing focus on healthcare reform, particularly in the context of drug pricing. The agreements are part of a broader strategy to address costs associated with pharmaceuticals.
As the White House moves forward, the implications of these deals for patients and the healthcare system will be closely monitored, especially in light of ongoing discussions about drug affordability.
Updates
Update at 13:36 UTC on 2026-04-24
STAT reported President Trump heralded a drug-pricing agreement with Regeneron, closing the last of 17 deals sought by the White House.
Sources: STAT